Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する実験動画

トロンボシスとファクターIX濃縮剤

S J Machin, B E Miller

    Lancet (London, England)
    |June 24, 1978
    PubMed
    まとめ

    No abstract available in PubMed .

    関連する実験動画

    関連する概念動画

    こちらも読む

    関連記事

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    並び替え
    Same author

    BMI- and age-related associations with mortality from COVID-19.

    Anaesthesia·2021
    Same author

    A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

    International journal of laboratory hematology·2017
    Same author

    ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

    International journal of laboratory hematology·2017
    Same author

    Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

    Journal of thrombosis and haemostasis : JTH·2016
    Same author

    Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

    Leukemia & lymphoma·2016
    Same author

    Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

    Journal of thrombosis and haemostasis : JTH·2015
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    関連記事をすべて見る